{'fraction_non_alphanumeric': 0.03472714386959603, 'fraction_numerical': 0.002834868887313962, 'mean_word_length': 5.788461538461538, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Perspective design of chalcones for the management of CNS disorders: A mini-review.

The development of chalcone based compounds for CNS disorders have been explored by many research groups. Chalcones are being considered as a potent organic scaffold with wide spread applications in the field of drug discovery and medicinal chemistry. The planar or semi-planar geometry of chalcones with various functionalities impinged on the terminal aromatic systems bring the molecule towards its bio-activity with special reference to anti-cancer, anti-malarial, anti-microbial, anti-fungal, anti-leishmanial, anti-viral, anti-diabetic, anti-hypertensive etc. Moreover, cutting-edge research has been executed in the domain of central nervures system (CNS) based scheme, further, its identification and classifications are also remains of high interest in the field of medicinal chemistry but their specific reviews are limited. Hence the present review highlights the significance of chalcones toward its CNS activities (up to 2016), which incorporate anti-depressant, anxiolytic activity, activity with GABA receptors, acetylcholinesterase (AChE) and butyryl cholinesterase (BChE) inhibitions, adenosine receptor antagonists anti-alzheimer's agents, β-amyloid plaques imaging agents, monoamine oxidase inhibition. In our knowledge and belief this is the first review exclusively for CNS activity profile for chalcones.